Research Of OROS MPH In Children With Attention Deficit Hyperactivity Disorder

Objective: To study the efficacy and safety of OROSMPH(methylphenidate HCI extended-release tablets)in childrenwith attention deficit /hyperactivity disorder(ADHD). Background: ADHD is one of the most commonchildhood-onset psychiatric disorders and affects approximately3~10% of school age children. Standardized criteria have beenestablished for disgnosis of ADHD.This disorder is characterizedby symptoms of inattention,hyperactivity and impulsivity. Weusually use integrated therapy to treat ADHD, including behaviortherapy and medication. Methylphenidate(MPH) is the drug offirst choice used in the treatment of ADHD. MPH enhances therelease and blocks the reuptake of dopamine(DA) andnorepinephrine(NE) in mammalian brain.Recently, it has beendemonstrated that it interacts with both the DA transporter andvesicle trafficking in the DA terminals. To study the efficacy ofthis drug in the children and to assess adverse events associatedwith its administration, we designed a descriptive study of 29children treated for ADHD in the same treatment setting andmonitored by a team of pediatric neurologists. Methods: 29 children with ADHD, all subtypes, aged 6 to 14years, participated in a opened clinical trial. The diagnosis ofADHD was made according to the 4th edition of DiagnositcStatistical Manual of Mental Disorder Criteria. Patients weretreated for 6 weeks by OROS MPH.The efficacy assessmentwascarried out by parent symptom questionnaire(PSQ) and parentscontentment degree research, and measured by the parents'estimation and the doctors' clinical examination at the time pointsof 0,2nd,4th and 6th weeks respectively.Before treatment andafter treatment, we measured the blood routine, urine routine toassess the safety of OROS MPH.Results: The efficacy rate in OROS MPH group was 75.9%,which is similiar MPH 's that had been reported previously. Thechange of scores of hyperkinetic index and PSQ manifestistedthat OROS MPH had a relatively better clinic effects towards thesymptoms such as in attention and abnormal behaviors. Thescores of hyperkinetic and behavior were decreased obviously(PSQ) (P<0.01). The parents had been more satisfied with OROSMPH in efficacy, safety and once a day administration. Moreover,the soft nerve signs were significantly improved and theside-effect occurred we found that no extrapyramidal side effectwas found.Conclusion: OROS MPH which is superior to MPH as oncea day administration is an effective and safe drug in the treatmentof ADHD.